At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Aurstat Anti-Itch Hydrogel (Aurstat)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-Day Investigator Blinded, Randomized Study Evaluating Aurstat Anti-Itch Hydrogel Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus
The Center for Clinical and Cosmetic Research·interventional·Posted Jul 23, 2013·Updated Oct 24, 2022
In Brief
A Phase 2 clinical trial evaluating Aurstat Anti-Itch Hydrogel (Aurstat) for Pruritus and Atopic Dermatitis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for tolerability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus, Atopic Dermatitis
CountriesUnited States
CollaboratorsOnset Dermatologics, Inc.
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionSep 2013
TodayJul 2026
First PostedJul 23, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.9 years ago
Interventions
Aurstat Anti-Itch Hydrogel (Aurstat)drug
Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.